CardioTech expands heart bypass graft trial:
This article was originally published in Clinica
Executive Summary
CardioTech is expanding the feasibility trial of its coronary artery bypass graft, following the recent positive results of its first few patients. The Woburn, Massachusetts firm plans to implant 20 patients with the CardioPass graft, as part of its trial, which is being conducted in Brazil and Chile. The graft is made of microporous polyurethane, designed to be kink resistant. CardioTech is one of only two firms - the other Pleasanton, being California-based Thoratec - pursuing clinical trials of a synthetic artery bypass graft, which will target a potential market believed to be worth $1.5bn annually.